Summary:
- RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 2.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
AstraZeneca said its University of Oxford-partnered coronavirus vaccine was 70% effective, on average, in a study — leading shares to dive Monday. Some patients saw 90% effectiveness.
Mark Howard, BNP Paribas Multi-Asset Specialist, joined Yahoo Finance Live to discuss today's market action and what he's expecting heading into 2021.
Dr. Amesh Adalja, senior scholar at Johns Hopkins center for health security, joined Yahoo Finance Live to discuss the latest developments regarding a COVID-19 vaccine and the surge of COVID-19 cases accross the United States.
Dr. Sara Andrabi, Assistant Professor of Emergency Medicine at Baylor College of Medicine joins Yahoo Finance's Kristin Myers to break down the latest coronavirus developments as hopes of a vaccine continue to rise.
There have been growing concerns the very low-temperature requirements for the promising Covid-19 vaccine candidates developed by Pfizer and Moderna will lead to storage and logistics challenges that may hinder access to these vaccines in most parts of Africa and other developing regions, even in rural parts of developed countries. The Pfizer and Moderna candidate, which have both been reported to be 95% effective in stopping Covid-19 transmission, require ultra-cold storage of -80 oC and -20 ...
(Bloomberg Opinion) -- Max Nisen and Sam Fazeli, who cover the pharmaceutical industry for Bloomberg Opinion and Bloomberg Intelligence, answered questions about Covid-19 vaccine trial data released early Monday by AstraZeneca Plc and the University of Oxford. The dialog has been edited and condensed.Astra and Oxford on Monday became the third Covid-19 vaccine developers to announce positive early results from a large trial. But the findings don’t seem as straightforward or uniformly encouraging...
AstraZeneca’s shares fell more than 3% on Monday after vaccine efficacy results found an average 70% effectiveness in preventing the virus, a rate much lower compared with efficiency rates of above 90% among its two biggest rivals – Moderna and Pfizer.
Yahoo Finance’s Brian Sozzi, Julie Hyman, and Myles Udland speak with AstraZeneca EVP of Biopharmaceuticals, Ruud Dobber, about the company’s COVID-19 vaccine.
The global case tally for the coronavirus illness COVID-19 rose to 58.7 million on Monday and the U.S. tally rose above 12 million, with new daily infections heading toward 200,0000 a day amid growing fears that Thanksgiving travel will spark another surge.
Covid-19 patients hoping to avoid the hospital now have a second antibody treatment available to them.